Holen Sie sich die Stockscreener-App
18.54
8.94%
-1.82
Handel nachbörslich:
18.54
Schlusskurs vom Vortag:
$20.36
Offen:
$20.34
24-Stunden-Volumen:
543.60K
Relative Volume:
0.54
Marktkapitalisierung:
$564.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-3.614
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
-11.84%
1M Leistung:
+10.16%
6M Leistung:
+38.26%
1J Leistung:
+16.46%
1-Tages-Spanne:
$18.36
$20.34
1-Wochen-Bereich:
$18.36
$21.05
52-Wochen-Spanne:
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
18.54 | 620.29M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.3%Time to Sell? - MarketBeat
Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics - Yahoo Finance
Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Drops By 16.6% - MarketBeat
5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close - Yahoo Finance
KROS or ARGX: Which Is the Better Value Stock Right Now? - sharewise.com
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
Keros Therapeutics Reports Strong Revenue Growth - MSN
Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily
Assenagon Asset Management S.A. Has $4.07 Million Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Keros Therapeutics (NASDAQ:KROS) Raised to “Hold” at TD Cowen - Defense World
Keros Therapeutics (NASDAQ:KROS) Upgraded at TD Cowen - MarketBeat
Can Keros Therapeutics Inc. stock deliver consistent earnings growthJuly 2025 Chart Watch & Fast Gaining Stock Reports - Улправда
How rising interest rates impact Keros Therapeutics Inc. stockJuly 2025 Snapshot & Long-Term Capital Growth Ideas - DonanımHaber
Keros Therapeutics (NASDAQ:KROS) Trading Down 3.7%Here's Why - MarketBeat
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 - The Globe and Mail
Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros - sharewise.com
Keros Therapeutics Earnings Notes - Trefis
TFG Asset Management GP Ltd Sells 55,000 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares - MSN
Responsive Playbooks and the KROS Inflection - Stock Traders Daily
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? - sharewise.com
KROS vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
Stocks showing market leadership: Keros Therapeutics earns 92 RS rating - MSN
Keros Therapeutics, Inc. $KROS Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Keros Therapeutics, Inc. $KROS Stock Holdings Lowered by Federated Hermes Inc. - MarketBeat
Aug Summary: How Keros Therapeutics Inc stock performs in interest rate cyclesWeekly Trade Report & Daily Profit Focused Screening - moha.gov.vn
Myelofibrosis Market to Expand Significantly by 2034, States DelveInsight Report | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart.com
Stocks to watch: Keros Therapeutics sees relative strength rating rise to 82 - MSN
Would You Still Hold Keros Therapeutics Stock If It Fell 30%? - Trefis
Can Keros Therapeutics Stock Hold Up When Markets Turn? - Trefis
Keros Therapeutics (NASDAQ:KROS) Trading Up 12%Here's Why - MarketBeat
There's No Escaping Keros Therapeutics, Inc.'s (NASDAQ:KROS) Muted Revenues Despite A 30% Share Price Rise - 富途牛牛
How Keros Therapeutics Inc. stock benefits from tech adoptionWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - Newser
Franklin Resources Inc. Grows Stake in Keros Therapeutics, Inc. $KROS - Defense World
Will Keros Therapeutics Inc. stock outperform growth indexesBull Run & Fast Momentum Entry Tips - Newser
Top investors say Keros Therapeutics Inc (KROS) ticks everything they need - setenews.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily
TD Cowen Downgrades Keros Therapeutics (KROS) - MSN
Keros Therapeutics (KROS) Gets a Hold from Bank of America Securities - The Globe and Mail
Bank of America Increases Keros Therapeutics (NASDAQ:KROS) Price Target to $19.00 - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Price Target Raised to $19.00 at Bank of America - Defense World
B of A Securities Maintains Keros Therapeutics (KROS) Neutral Recommendation - Nasdaq
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN
KROS or NVZMY: Which Is the Better Value Stock Right Now? - MSN
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):